FTC expert says drugmakers’ settlement evolved too fast
The Federal Trade Commission’s expert witness said on Tuesday that a 2010 co-promotional agreement between Impax and rival drugmaker Endo was highly unusual because the agreement to pay Impax $10 million to develop a Parkinson’s drug occurred after only one month of negotiations.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10